Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2024-09-30 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement from the 2024 first extraordinary shareholders' meeting of the company. It details the meeting date, attendance, voting results on various proposals, and legal witness statements confirming the validity of the meeting and resolutions. There is no financial data or report content, but rather the official announcement of voting results and meeting resolutions. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2024-09-30 Chinese
健民集团2024年第一次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as materials for the "2024 First Extraordinary General Meeting" of the company. It includes detailed agenda items, voting procedures, and multiple proposals to be discussed and voted on by shareholders. The content covers topics such as the reappointment of the financial audit firm, approval of asset pool business, amendments to the company's articles of association, and revisions to board meeting rules. The document is clearly a set of meeting materials prepared for a shareholders' meeting, not a report or announcement of results. It is not a transcript, financial report, or regulatory filing. Therefore, it fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting.
2024-09-23 Chinese
健民集团第十届董事会第二十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 健民药业集团股份有限公司 (Jianmin Pharmaceutical Group Co., Ltd.). It details voting results on various proposals such as stock incentive plan unlocking, appointment of the audit firm, business scope changes, amendments to company bylaws, and scheduling a shareholders meeting. The document does not contain financial statements or detailed financial data but rather reports decisions made by the board. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation or voting results announcement from a shareholder meeting, but a board meeting resolution announcement. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short (1793 characters), consistent with a meeting resolution announcement rather than a full report.
2024-09-13 Chinese
健民集团关于开展资产池业务的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 健民药业集团股份有限公司 regarding the initiation and details of an asset pool business with a bank, including credit limits, guarantees, risk controls, and approval procedures. It includes financial data and operational details but does not present itself as a full financial report like an annual or interim report. It is not a simple notice of report publication or certification. The content focuses on financing activities related to asset pooling and credit facilities, which aligns with updates on company financing activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2024-09-13 Chinese
湖北得伟君尚律师事务所关于健民药业集团股份有限公司2022年限制性股票激励计第二个解锁期解锁条件成就的法律意见书
Regulatory Filings
2024-09-13 Chinese
健民药业集团股份有限公司高级管理人员薪酬与考核管理办法
Remuneration Information Classification · 95% confidence The document is titled '高级管理人员薪酬与考核管理办法' which translates to 'Senior Management Compensation and Assessment Management Measures'. It details the principles, structure, decision-making procedures, assessment, adjustment mechanisms, and supervision related to senior management compensation at the company. It is a policy or governance document about executive remuneration and related management processes. There is no financial data, no audit information, no earnings or annual report content, no voting results, no legal proceedings, no capital changes, and no meeting materials. The content fits the description of a Remuneration Information report, which details compensation for top executives and directors.
2024-09-13 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.